China’s Sinovac Biotech will trial its COVID-19 vaccine in children and adolescents in South Africa on Friday as part of a global study.
The first participant will receive their jab at the Sefako Makgatho Health Sciences University in Pretoria.
The study will evaluate the efficacy, immunogenicity, and safety of the CoronaVac vaccine on children and adolescents aged between six months and 17 years old.
The global trial will enrol 14,000 participants across Chile, the Philippines, Malaysia and Kenya – including 2,000 in South Africa.
The trial has been approved by the South African Health Products Regulatory Authority.
In other news – Minister Phaahla: Vaccine campaign to be integrated with voter registration weekend
Health Minister Joe Phaahla on Friday said the government planned to integrate the voter registration weekend with the COVID-19 vaccination campaign.
The registration weekend has been set down for the 18 and 19 September. Learn more